193952-29-3

Upstream product

• 5545-52-8 Z-D(tBu)-OH 
• 202653-53-0 methyl 2-[(2,2-dimethoxyethyl)amino]acetate 

Downstream Products

• 193952-41-9 C₆₅H₈₁N₉O₁₅ 
• 1026499-38-6 C₆₅H₈₁N₉O₁₅ 
• 1025815-82-0 C₆₄H₇₉N₉O₁₅ 
• 193952-39-5 C₆₃H₇₈N₈O₁₄ 
• 194030-22-3 3-{2-[(5S,11S,17S)-11-tert-Butoxymethyl-13-(2,2-dimethoxy-ethyl)-3,6,9,12,15,18-hexaoxo-17-(1-trityl-1H-imidazol-4-ylmethyl)-1,4,7,10,13,16-hexaaza-tricyclo[14.2.2.2^4,7]docos-5-yl]-acetylamino}-propionic acid tert-butyl ester 
• 194030-21-2 {2-[(5S,11S,17S)-11-tert-Butoxymethyl-13-(2,2-dimethoxy-ethyl)-3,6,9,12,15,18-hexaoxo-17-(1-trityl-1H-imidazol-4-ylmethyl)-1,4,7,10,13,16-hexaaza-tricyclo[14.2.2.2^4,7]docos-5-yl]-acetylamino}-acetic acid tert-butyl ester 
• 1026710-79-1 ((S)-4-{2-[(S)-4-{2-[((S)-2-Amino-3-tert-butoxy-propionyl)-(2,2-dimethoxy-ethyl)-amino]-acetyl}-2-oxo-3-(1-trityl-1H-imidazol-4-ylmethyl)-piperazin-1-yl]-acetyl}-3-tert-butoxycarbonylmethyl-2-oxo-piperazin-1-yl)-acetic acid 
• 194030-19-8 [(5S,11S,17S)-11-tert-Butoxymethyl-13-(2,2-dimethoxy-ethyl)-3,6,9,12,15,18-hexaoxo-17-(1-trityl-1H-imidazol-4-ylmethyl)-1,4,7,10,13,16-hexaaza-tricyclo[14.2.2.2^4,7]docos-5-yl]-acetic acid tert-butyl ester 
• 193952-37-3 (S)-2-[(2-tert-Butoxycarbonyl-ethylcarbamoyl)-methyl]-4-methoxycarbonylmethyl-3-oxo-3,4-dihydro-2H-pyrazine-1-carboxylic acid benzyl ester 
• 193952-36-2 (S)-2-[(tert-Butoxycarbonylmethyl-carbamoyl)-methyl]-4-methoxycarbonylmethyl-3-oxo-3,4-dihydro-2H-pyrazine-1-carboxylic acid benzyl ester 
• 1025810-45-0 (S)-2-Carboxymethyl-4-methoxycarbonylmethyl-3-oxo-3,4-dihydro-2H-pyrazine-1-carboxylic acid benzyl ester 
• 193952-42-0 C₆₆H₈₃N₉O₁₅ 
• 193952-33-9 (S)-2-tert-Butoxycarbonylmethyl-4-methoxycarbonylmethyl-3-oxo-3,4-dihydro-2H-pyrazine-1-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2- oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide

Based on the lead tetrapeptide RGDF, two possible non-peptide glycoprotein (GP) IIb-IIIa antagonists possessing an (S)-2-oxopiperazine-3- acetic acid moiety as a scaffold incorporating the indispensable Asp fragment were prepared, and (S)-4-[[trans-[4-(gu